Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

AnaptysBio Announces Proposed Public Offering of Common Stock

GlobeNewswire September 24, 2018

24 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  September 24, 2018

AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma

GlobeNewswire September 24, 2018

The Week Ahead In Biotech (Sept. 23-29): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Benzinga.com  September 23, 2018

AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates

GlobeNewswire August 7, 2018

AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 6, 2018

AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 30, 2018

AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress

GlobeNewswire May 29, 2018

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

GlobeNewswire May 8, 2018

AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress

GlobeNewswire May 1, 2018

AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

GlobeNewswire March 26, 2018

AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones

GlobeNewswire March 5, 2018

7 Biotech Stocks With Clinical Trial Outcomes In March

Benzinga.com  March 5, 2018

7 Big Companies That Could Tap The IPO Markets In 2018

Benzinga.com  February 22, 2018

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

GlobeNewswire February 17, 2018

AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

GlobeNewswire February 7, 2018

Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC — Discovering Underlying Factors of Influence

GlobeNewswire January 18, 2018

AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference

GlobeNewswire January 2, 2018

Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen, Alexion Pharma, AnaptysBio, and Akcea Therapeutics

PR Newswire December 14, 2017

AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates

GlobeNewswire November 7, 2017